Blair William & Co. IL boosted its position in Aduro Biotech, Inc. (NASDAQ:ADRO) by 12.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 213,595 shares of the biotechnology company’s stock after buying an additional 23,805 shares during the period. Blair William & Co. IL owned about 0.31% of Aduro Biotech worth $2,435,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the company. Wellington Management Group LLP increased its stake in Aduro Biotech by 9.1% in the first quarter. Wellington Management Group LLP now owns 9,448,529 shares of the biotechnology company’s stock worth $101,571,000 after buying an additional 791,770 shares during the last quarter. Norges Bank purchased a new stake in Aduro Biotech during the fourth quarter worth approximately $3,266,000. Goldman Sachs Group Inc. increased its stake in Aduro Biotech by 330.5% in the first quarter. Goldman Sachs Group Inc. now owns 236,721 shares of the biotechnology company’s stock worth $2,545,000 after buying an additional 181,734 shares during the last quarter. Renaissance Technologies LLC increased its stake in Aduro Biotech by 762.1% in the first quarter. Renaissance Technologies LLC now owns 181,900 shares of the biotechnology company’s stock worth $1,955,000 after buying an additional 160,800 shares during the last quarter. Finally, Highbridge Capital Management LLC purchased a new stake in Aduro Biotech during the first quarter worth approximately $853,000. Institutional investors own 33.48% of the company’s stock.

Shares of Aduro Biotech, Inc. (NASDAQ ADRO) opened at 11.00 on Friday. The stock’s market capitalization is $820.73 million. The stock has a 50 day moving average price of $12.34 and a 200 day moving average price of $10.95. Aduro Biotech, Inc. has a 12 month low of $8.75 and a 12 month high of $15.83.

Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.02. Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The firm had revenue of $5.90 million during the quarter, compared to the consensus estimate of $3.98 million. During the same quarter in the prior year, the company earned $0.03 EPS. Aduro Biotech’s quarterly revenue was down 84.9% on a year-over-year basis. On average, analysts anticipate that Aduro Biotech, Inc. will post ($1.37) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Aduro Biotech, Inc. (ADRO) Shares Bought by Blair William & Co. IL” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://theolympiareport.com/2017/08/26/aduro-biotech-inc-adro-shares-bought-by-blair-william-co-il.html.

ADRO has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Tuesday, July 4th. Rodman & Renshaw initiated coverage on Aduro Biotech in a research report on Monday, May 1st. They set a “buy” rating and a $18.00 target price on the stock. BidaskClub upgraded Aduro Biotech from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. HC Wainwright initiated coverage on Aduro Biotech in a research report on Monday, May 1st. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, Cowen and Company initiated coverage on Aduro Biotech in a research report on Tuesday, July 18th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. Aduro Biotech has a consensus rating of “Buy” and a consensus price target of $19.00.

In related news, insider Thomas W. Dubensky sold 144,301 shares of the company’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $10.03, for a total value of $1,447,339.03. Following the completion of the sale, the insider now owns 117,871 shares in the company, valued at approximately $1,182,246.13. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Thomas W. Dubensky sold 40,912 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $11.43, for a total transaction of $467,624.16. Following the completion of the sale, the insider now owns 80,812 shares of the company’s stock, valued at approximately $923,681.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 561,624 shares of company stock valued at $6,232,065. 6.60% of the stock is owned by corporate insiders.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Want to see what other hedge funds are holding ADRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aduro Biotech, Inc. (NASDAQ:ADRO).

Institutional Ownership by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.